Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Alvotech (ALVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: ALVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $17.9
1 Year Target Price $17.9
| 2 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.5% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.70B USD | Price to earnings Ratio 23.62 | 1Y Target Price 17.9 |
Price to earnings Ratio 23.62 | 1Y Target Price 17.9 | ||
Volume (30-day avg) 4 | Beta 0.19 | 52 Weeks Range 7.35 - 13.70 | Updated Date 07/10/2025 |
52 Weeks Range 7.35 - 13.70 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.42% | Operating Margin (TTM) 7.97% |
Management Effectiveness
Return on Assets (TTM) 7.02% | Return on Equity (TTM) - |
Valuation
Trailing PE 23.62 | Forward PE 43.48 | Enterprise Value 3891733616 | Price to Sales(TTM) 4.6 |
Enterprise Value 3891733616 | Price to Sales(TTM) 4.6 | ||
Enterprise Value to Revenue 6.65 | Enterprise Value to EBITDA 28.03 | Shares Outstanding 309305984 | Shares Floating 100126591 |
Shares Outstanding 309305984 | Shares Floating 100126591 | ||
Percent Insiders 63.44 | Percent Institutions 6.44 |
Upturn AI SWOT
Alvotech
Company Overview
History and Background
Alvotech is a biopharmaceutical company focused on developing and manufacturing biosimilar medicines. Founded in 2012, it aims to improve patient access to affordable biological treatments. Alvotech merged with Oaktree Acquisition Corp. II in 2022, becoming publicly listed.
Core Business Areas
- Biosimilar Development: Developing biosimilar versions of major biologic drugs. Focused on oncology, immunology, and ophthalmology.
- Manufacturing: Operates its own manufacturing facilities to produce biosimilar products.
- Commercialization: Partners with other pharmaceutical companies for commercialization and distribution of its products.
Leadership and Structure
Robert Wessman serves as Chairman and CEO. The company has a structured management team overseeing research, development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- AVT02 (adalimumab biosimilar): Biosimilar to Humira (adalimumab). Targeting inflammatory diseases. Competitors include Amgen's Amjevita, Boehringer Ingelheim's Cyltezo, and others. Alvotech has faced legal challenges regarding patent infringement.
- AVT04 (ustekinumab biosimilar): Biosimilar to Stelara (ustekinumab). Targeting inflammatory diseases. Still in development. Competitors include Amgen and other biosimilar developers.
Market Dynamics
Industry Overview
The biosimilar market is experiencing significant growth due to patent expirations of originator biologics and increasing demand for lower-cost treatment options. High barriers to entry exist due to complex manufacturing and regulatory requirements.
Positioning
Alvotech aims to be a leading player in the global biosimilar market by developing and commercializing a portfolio of high-quality, affordable biosimilar products. They are focusing on major markets and partnering to expand their reach.
Total Addressable Market (TAM)
The global biosimilars market is projected to reach over $100 billion by 2030. Alvotech's positioning is to capture a significant share of this growing market by focusing on high-value biosimilars and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong focus on biosimilar development
- Advanced manufacturing capabilities
- Strategic partnerships for commercialization
- Experienced management team
- Focus on high value biosimilars
Weaknesses
- Reliance on partnerships for commercialization
- Dependence on successful regulatory approvals
- Limited operating history as a publicly listed company
- Competition from established pharmaceutical companies
- Ongoing patent litigation
Opportunities
- Growing biosimilar market
- Patent expirations of major biologics
- Expansion into new markets
- Development of new biosimilars
- Increasing adoption of biosimilars by healthcare providers
Threats
- Intense competition
- Patent litigation
- Regulatory hurdles
- Price erosion in the biosimilar market
- Slower than expected biosimilar adoption
Competitors and Market Share
Key Competitors
- AMGN
- PFE
- BMY
- VTRS
Competitive Landscape
Alvotech competes with established pharmaceutical companies in the biosimilar market. Its advantage lies in its focus on biosimilars and manufacturing capabilities. Its disadvantages include reliance on partnerships and smaller scale.
Major Acquisitions
Strada Biopharma
- Year: 2020
- Acquisition Price (USD millions): 0
- Strategic Rationale: Alvotech obtained exclusive rights in the U.S. to commercialize a portfolio of biosimilar candidates, including biosimilars to Humira, Stelara, and Eylea.
Growth Trajectory and Initiatives
Historical Growth: Alvotech's historical growth is marked by R&D progress and strategic partnerships. Revenue growth has been driven by initial product launches.
Future Projections: Future growth is projected based on the launch and adoption of its biosimilar portfolio. Analyst estimates suggest substantial revenue growth as more products reach the market.
Recent Initiatives: Recent initiatives include securing regulatory approvals for AVT02, expanding manufacturing capacity, and strengthening partnerships.
Summary
Alvotech is a biopharmaceutical company with potential in the growing biosimilars market. While it faces challenges related to competition, patent litigation, and regulatory approvals, its strategic partnerships and focus on high-value biosimilars position it for long-term growth. The company's future success hinges on its ability to successfully navigate these challenges and commercialize its product pipeline. Alvotech is still in early stages of growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Actual results may vary significantly from projections due to market conditions and other factors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alvotech
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-06-16 | CEO, Founder & Executive Chairman Mr. Robert Wessman | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1012 | Website https://www.alvotech.com |
Full time employees 1012 | Website https://www.alvotech.com | ||
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.